Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's President and Chief Executive Officer, Robert I. Blum, will engage in a virtual fireside chat scheduled for Wednesday, February 12, 2025, at 4:40 PM Eastern Time.

Interested participants can access the live webcast through the Investors & Media section of Cytokinetics' website. Following the event, the webcast recording will remain accessible on the company's website for a 90-day period.

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 35^th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:40 PM Eastern Time.

Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.

About Cytokinetics

Cytokinetics is a late-stage, muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a potential next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

When is Cytokinetics (CYTK) presenting at the Oppenheimer Healthcare Conference 2025?

Cytokinetics (CYTK) is scheduled to present at the Oppenheimer Healthcare Conference on Wednesday, February 12, 2025, at 4:40 PM Eastern Time.

How long will the CYTK Oppenheimer Conference webcast be available for replay?

The webcast replay will be archived on Cytokinetics' website for 90 days following the conclusion of the event.

Where can investors watch the CYTK Oppenheimer Conference presentation?

Investors can access the live webcast through the Investors & Media section of Cytokinetics' website at www.cytokinetics.com.

What type of presentation will CYTK give at the Oppenheimer Healthcare Conference?

CYTK will participate in a virtual fireside chat format presentation at the conference.